Drug · CHEMBL104
CLOTRIMAZOLE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CLOTRIMAZOLE. Drugs and targets, record CHEMBL104. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL104
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Abtrim, Actavall, Candiden, Canesten, Canesten af, Canesten crm combi, Canesten internal, Canesten vc, Clotrimazole component of lotrisone, Fungederm, Gyne-lotrimin, Gyne-lotrimin 3, Gyne-lotrimin 3 combination pack, Gyne-lotrimin combination pack, Gynix, Masnoderm, Mycelex, Mycelex-7, Mycelex-7 combination pack, Mycelex-g, Mycil gold, Privacom, Trimysten, Trivagizole 3
- ChEMBL
- Other names
- BAY 5097, BAY-5097, Clotrimazol, GNF-PF-3499, Lotrimin, NSC-257473, SVT-15652, Svt-15652, Trivagizole
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials38
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02180828 | Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis | Phase 4 | 240 | 2016-09-30 | clotrimazole | Its name | ClinicalTrials.gov |
| NCT03686384 | SVT-15652 Otic Solution for the Treatment of Otomycosis | Phase 3 | 217 | 2023-01-18 | SVT-15652 | Its name | ClinicalTrials.gov |
| NCT03686397 | SVT-15652 Otic Solution for the Treatment of Otomycosis. | Phase 3 | 194 | 2022-12-15 | svt-15652 | Its name | ClinicalTrials.gov |
| NCT01993823 | Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis | Phase 3 | 190 | 2017-02-13 | clotrimazole | Its name | ClinicalTrials.gov |
| NCT00671528 | Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) | Phase 4 | 3 | 2011-06-16 | clotrimazole | Its name | ClinicalTrials.gov |
| NCT06349122 | AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth | Phase 3 | 1,794 | clotrimazole | Its name | ClinicalTrials.gov | |
| NCT00000676 | Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) | Phase 3 | 500 | clotrimazole | Its name | ClinicalTrials.gov | |
| NCT00755053 | Comparative Efficacy of Ovule vs Tablet | Phase 3 | 466 | clotrimazole | Its name | ClinicalTrials.gov | |
| NCT07441005 | Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract | Early phase 1 | 386 | clotrimazole | Its name | ClinicalTrials.gov | |
| NCT02635438 | A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. | Phase 3 | 360 | clotrimazole | Its name | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Clotrimazole Vaginal Tablet vs Fluconazole: Adverse Events 3 | 3 of 115 | 3 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Adverse Events 4 | 0 of 115 | 3 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Total Adverse Events | 16 of 115 | 12 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Adverse Events 2 | 12 of 115 | 1 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Adverse Events 1 | 1 of 115 | 9 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: serious adverse events | 0 of 115 | 0 of 113 | 228 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Therapeutic Efficacy 3 | 90 of 115 | 81 of 110 | 225 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Therapeutic Efficacy 1 | 102 of 114 | 98 of 110 | 224 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Therapeutic Efficacy 2 | 82 of 114 | 85 of 109 | 223 | NCT02180828 | Trial comparisons |
| Clotrimazole Vaginal Tablet vs Fluconazole: Therapeutic Efficacy 4 | 62 of 114 | 61 of 109 | 223 | NCT02180828 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials4
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL104
GET https://conductscience.org/api/drugs/v1/CHEMBL104/trials?page=2